Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pulmonary Disease, Chronic Obstructive
Intervention: fluticasone propionate/salmeterol xinafoate combination (Drug)
Phase: N/A
Status: Completed
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s): GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
Summary
The specific aim of this study is to describe 1 year Advair dispensing rates for patients
with COPD, and to measure the association between Advair adherence and healthcare
utilization (e. g. emergency room visits and inpatient admissions, etc.). To compare the risk
of a COPD exacerbation (moderate or severe) during a 3-month follow-up period between
patients thqat are adherent versus those that are not.
Clinical Details
Official title: Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Study design: Observational Model: Cohort, Time Perspective: Retrospective
Primary outcome: Mean Number of Pharmacy Claims by Participants During the Post-Index PeriodMean Number of Healthcare Encounters Incurred by Participants During the Post-Index Period
Eligibility
Minimum age: 40 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
INCLUSION CRITERIA
- at least one pharmacy claim for Advair (any strength; Diskus or MDI) during the index
year (July 1, 2005 through June 30, 2006).
- Continuous medical and pharmacy eligibility for the 12 month Pre-Index year and the
12 month Index year (referred to as the 24 month Observation Period), and the 3 month
Post-Index period (referred to as the Outcome Period).
- At least one medical claim with a diagnosis (either primary or secondary) of COPD
(ICD-9 code 490. xx, 491. xx, 492. xx, and 496), AND at least 1 pharmacy claim for an
Anticholinergic medication, both occurring during the12 month pre-index period.
- At least 40 years old at index date.
EXCLUSION CRITERIA
- any medical claim (ever) with a primary or secondary diagnosis of cystic fibrosis
(ICD-9 code 277. 0x).
Locations and Contacts
Additional Information
Starting date: August 2009
Last updated: March 15, 2012
|